Lumpy SalesAccording to Samira, the quarterly top-line will be lumpy for numerous reasons, such as:
- They’re not sure of the impact of Covid, obviously.
- Large markets going to winter.
- Transitioning to Exelon in Colombia (already happened in May) and Brazil (in June).
However, they “know” they’re going to hit the revenue guidance, just not sure how it will look on a quarterly basis.
As far as the salesforce goes, there was little traditional sales activity in the beginning of Q1. However, “everyone went back into the field” by the end of Q1. So, we can certainly expect increased costs in the near-term (affecting EBITDA margins) but (hopefully!) increased sales and EBITDA in the long run.
”In Q1-22 Knight field teams across most of the countries, have increased field activities including in-person medical visits to physicians and increased volume of such activities is expected in the future. The Company started returning to the office on a country-by-country basis using a hybrid work model following the developed protocols to ensure compliance with local regulations, ensuring safety of employees, patients and healthcare professionals.”